A large pharmaceutical company was conducting a Phase 2 study for adults with a BMI of 18-32. They contracted 60 US sites, including 9 Accellacare sites to recruit for two cohorts and conduct the study.

While obesity studies may be an easier indication to recruit for, given the prevalence, the sponsor had a challenge meeting enrolment targets for male patients. In addition, the study required patient imaging before randomisation could be completed and there were study-wide challenges with scheduling the imaging in a timely manner.

In addition, the second cohort increased the total number of sites, leading to overwhelming enrolment and many sites were capped by the sponsor before meeting their targets. Having additional sites with fewer patients lead to faster enrolment, but also increased costs for the sponsor.

Accellacare Site Network had nine US sites contracted for this study. Accellacare has a widespread patient database via electronic medical records, which contributed 70% of our randomised patients. The remaining patients were recruited via digital campaigns, primarily though Facebook. In order to address the challenge with meeting gender targets, Accellacare developed a campaign to specifically drive male recruitment, and we were able to exceed our recruitment goals ahead of schedule.

Due to our patient database and recruitment strategies, Accellacare sites exceeded enrolment targets by 107%. On average, our sites recruited 11.3 patients per site (2.2 per month), compared to 9.8 for non-Accellacare sites (1.9 per month). Accellacare made up 17% of the total study enrolment, while accounting for 15% of total sites. We were able to randomise the first patient study-wide, and held a top 3 highest recruiting site overall.